Indo Us Bio-Tech First Quarter 2026 Earnings: EPS: ₹2.35 (vs ₹1.58 in 1Q 2025)

Indo Us Bio-Tech (NSE:INDOUS) First Quarter 2026 Results

Key Financial Results

• Revenue: ₹307.7m (up 25% from 1Q 2025).
• Net income: ₹47.0m (up 48% from 1Q 2025).
• Profit margin: 15% (up from 13% in 1Q 2025). The increase in margin was driven by higher revenue.
• EPS: ₹2.35 (up from ₹1.58 in 1Q 2025).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Indo Us Bio-Tech shares are down 6.7% from a week ago.

Risk Analysis

Be aware that Indo Us Bio-Tech is showing 3 warning signs in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.